In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...
New Scientist on MSN
I’m the first person whose life was saved by CRISPR base editing
When standard leukaemia treatments failed, 13-year-old Alyssa Tapley was told she had only weeks left – but then she was ...
Vertex has secured a label expansion through the FDA's Commis | Vertex Pharmaceuticals has gained a label expansion from the ...
FDA expands Casgevy CRISPR gene therapy to children aged 2+ with sickle cell disease and beta thalassemia, enabling earlier ...
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
9d
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...
New World screwworm cases continue to mount as researchers test a new sterile fly technology to improve future eradication ...
CRISPR Therapeutics stock has rebounded in the short term; however, over five years the share price is still significantly ...
CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results